Bill Would Bar 340B Upfront Payment Rebates

Reps. Jack Bergman and Raul Ruiz introduce legislation protecting a broader group of safety-net providers from rebate arrangements.

Updated on Nov. 11, 2026 in Healthcare

Isometric editorial illustration of unlabeled amber vials and blank cartons on a shelf, with a single coin resting on the edge, evoking upfront drug payment costs.
Reps. Jack Bergman and Raul Ruiz introduced H.R. 10919 on October 29 to bar 340B upfront-payment rebate arrangements for safety-net providers. AI Illustration. Upload story photo >

Live Poll

Should Congress shield rural hospitals and health centers from upfront drug-price rebate rules?

Reps. Jack Bergman and Raul Ruiz introduced the Safety Net Provider Drug Pricing Protection Act, H.R. 10919, on October 29. The bill would prohibit 340B arrangements requiring critical access hospitals, federally qualified health centers and sole community hospitals to pay above the ceiling price upfront and recover the difference through a rebate.

Why it matters

The release states the rebate model would force providers to buy drugs at full price and wait for reimbursement, creating financial and administrative burdens for smaller providers with limited reserves. The bill extends protection beyond H.R. 7391, which covers only federally qualified health centers.

HRSA has approved 10 drugmakers to participate in the 340B rebate pilot, and a separate House bill would delay the pilot by two years. The Safety Net Provider Drug Pricing Protection Act would extend its protections to critical access hospitals, federally qualified health centers and sole community hospitals.

The players

Jack Bergman

Republican U.S. Representative from Michigan who co-sponsored the Safety Net Provider Drug Pricing Protection Act.

Raul Ruiz

Democratic U.S. Representative from California who co-sponsored the Safety Net Provider Drug Pricing Protection Act.

National Association of Community Health Centers

National trade group representing federally qualified health centers that supports the bill.

The details

The bill would bar 340B arrangements that require upfront payment above the ceiling price followed by recovery through a rebate, reimbursement or other payment. Supporters include Aspirus Health, OSF St. Francis Hospital, Schoolcraft Memorial Hospital, Kalkaska Memorial Health Center, Munising Memorial Hospital, Helen Newberry Joy Hospital, Mackinac Straits Hospital, the Michigan Center for Rural Health and the National Association of Community Health Centers.

Timeline

  1. October 29, 2026: Bergman and Ruiz introduce H.R. 10919.

  2. November 11, 2026: Congressional office release announces the bill.

Legislative Context

The bill builds on H.R. 7391, the Community Health Center Drug Pricing Protection Act, which protects only federally qualified health centers. It extends that approach to critical access hospitals and sole community hospitals as HRSA's 340B rebate pilot, with ten approved drugmakers, faces lawsuits and a competing House proposal to delay it.

If enacted, the bill would shield critical access hospitals, federally qualified health centers and sole community hospitals from paying full price upfront for 340B drugs. The protection would ease cash-flow pressure on smaller providers that rely on reimbursement for their drug supply.

The takeaway

Watch whether H.R. 10919 advances alongside the rebate pilot litigation and the competing proposal to delay it, since those outcomes will determine how safety-net providers buy 340B drugs. Providers with limited cash reserves should track the bill's progress closely.

Further reading

For more on the broader policy fight, see Healthcare coverage across the United States.

Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.

Live Poll

Should Congress shield rural hospitals and health centers from upfront drug-price rebate rules?